The Transcription Factor AP-1 in Squamous Cell Carcinogenesis: Lessons from Mouse Models of Skin Carcinogenesis

  • Jochen Hess
  • Peter AngelEmail author


A large body of experimental and clinical data provides strong evidence for an important role of the activator protein-1 (AP-1) in normal epithelial development and homeostasis, and that deregulated AP-1 activity contributes to pathophysiological processes, including neoplastic transformation of keratinocytes and malignant progression of tumor cells. AP-1 is a dimeric transcription factor mainly composed of members of the Jun and Fos families, which are key nuclear targets of several signal transduction pathways, particularly those involving the activation of mitogen-activated protein kinases. The analysis of genetically modified mouse models and cell lines derived thereof has provided important new insights how Jun and Fos proteins regulate cellular processes of keratinocyte differentiation, proliferation, survival and neoplastic transformation. Although some direct AP-1 target genes such as matrix metalloproteinases have been identified, further genome-wide and functional approaches will be required to comprehensively understand the causal connectivity between altered AP-1 function and squamous cell carcinogenesis.


Neoplastic Transformation Egfr Signaling Skin Carcinogenesis Squamous Tumor Sebaceous Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Our work was supported by the German Ministry for Education and Research (National Genome Research Network NGFN-2), the Deutsche Krebshilfe e.V., the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Systems Biology, and by the Studienstiftung des deutschen Volkes.


  1. Aikawa Y, Morimoto K, Yamamoto T et al. (2008) Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 26:817–823CrossRefPubMedGoogle Scholar
  2. Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129–157PubMedGoogle Scholar
  3. Behrens A, Jochum W, Sibilia M et al. (2000) Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 19:2657–2663CrossRefPubMedGoogle Scholar
  4. Bos TJ, Bohmann D, Tsuchie H et al. (1988) v-jun encodes a nuclear protein with enhancer binding properties of AP-1. Cell 52:705–712CrossRefPubMedGoogle Scholar
  5. Bourcier C, Jacquel A, Hess J et al. (2006) p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res 66:2700–2707CrossRefPubMedGoogle Scholar
  6. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37–40CrossRefPubMedGoogle Scholar
  7. Chen N., Nomura, M., She, Q.B., Ma, W.Y., Bode, A.M., Wang, L., Flavell, R.A. and Dong, Z. (2001). Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 61:3908–3912PubMedGoogle Scholar
  8. Curran T, MacConnell WP, van Straaten F et al. (1983) Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol Cell Biol 3:914–921PubMedGoogle Scholar
  9. Dass CR, Galloway SJ, Clark JC (2008a) Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther 7:1297–1301PubMedGoogle Scholar
  10. Dass CR, Khachigian LM, Choong PF (2008b) c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol Cancer Res 6:1289–1292CrossRefPubMedGoogle Scholar
  11. Durchdewald M, Angel P, Hess J. (2009) The transcription factor Fos: a Janus-type regulator in health and disease. Histol Histopathol 24(11):1451–1461PubMedGoogle Scholar
  12. Durchdewald M, Guinea-Viniegra J, Haag D et al (2008) Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res 68:6877–6883CrossRefPubMedGoogle Scholar
  13. Eferl R, Ricci R, Kenner L et al. (2003) Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112:181–192CrossRefPubMedGoogle Scholar
  14. Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3:859–868CrossRefPubMedGoogle Scholar
  15. Eger A, Stockinger A, Park J et al. (2004) beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 23:2672–2680CrossRefPubMedGoogle Scholar
  16. Eger A, Stockinger A, Schaffhauser B et al. (2000) Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 148:173–188CrossRefPubMedGoogle Scholar
  17. Florin L, Hummerich L, Dittrich BT et al. (2004) Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing. Oncogene 23:7005–7017CrossRefPubMedGoogle Scholar
  18. Florin L, Knebel J, Zigrino P et al. (2006) Delayed wound healing and epidermal hyperproliferation in mice lacking JunB in the skin. J Invest Dermatol 126:902–911CrossRefPubMedGoogle Scholar
  19. Florin L, Maas-Szabowski N, Werner S et al. (2005) Increased keratinocyte proliferation by JUN-dependent expression of PTN and SDF-1 in fibroblasts. J Cell Sci 118:1981–1989CrossRefPubMedGoogle Scholar
  20. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342–346CrossRefPubMedGoogle Scholar
  21. Gebhardt C, Nemeth J, Angel P et al. (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72:1622–1631CrossRefPubMedGoogle Scholar
  22. Gerdes MJ, Myakishev M, Frost NA et al. (2006) Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res 66:7578–7588CrossRefPubMedGoogle Scholar
  23. Greenhalgh DA, Quintanilla MI, Orengo CC et al. (1993a) Cooperation between v-fos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion. Cancer Res 53:5071–5075PubMedGoogle Scholar
  24. Greenhalgh DA, Rothnagel JA, Wang XJ et al. (1993b) Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia. Oncogene 8:2145–2157PubMedGoogle Scholar
  25. Grigoryan G, Reinke AW, Keating AE (2009) Design of protein-interaction specificity gives selective bZIP-binding peptides. Nature 458:859–864CrossRefPubMedGoogle Scholar
  26. Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117:5965–5973CrossRefPubMedGoogle Scholar
  27. Hummerich L, Muller R, Hess J et al. (2006) Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 25:111–121PubMedGoogle Scholar
  28. Jimeno A, Kulesza P, Kincaid E et al. (2006) C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66:2385–2390CrossRefPubMedGoogle Scholar
  29. Kolev V, Mandinova A, Guinea-Viniegra J et al. (2008) EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 10:902–911CrossRefPubMedGoogle Scholar
  30. Li G, Gustafson-Brown C, Hanks SK et al. (2003) c-Jun is essential for organization of the epidermal leading edge. Dev Cell 4:865–877CrossRefPubMedGoogle Scholar
  31. Mason JM, Schmitz MA, Müller KM et al. (2006) Semirational design of Jun-Fos coiled coils with increased affinity: Universal implications for leucine zipper prediction and design. Proc Natl Acad Sci USA 103:8989–8994CrossRefPubMedGoogle Scholar
  32. Matthews CP, Birkholz AM, Baker AR et al. (2007) Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res 67:2430–2438CrossRefPubMedGoogle Scholar
  33. Mejlvang J, Kriajevska M, Berditchevski F et al. (2007) Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. Exp Cell Res 313:380–393CrossRefPubMedGoogle Scholar
  34. Reichmann E, Schwarz H, Deiner EM et al. (1992) Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 71:1103–1116CrossRefPubMedGoogle Scholar
  35. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for treatment of cancer. Oncogene 26:3291–3310CrossRefPubMedGoogle Scholar
  36. Saez E, Rutberg SE, Mueller E et al. (1995) c-fos is required for malignant progression of skin tumors. Cell 82:721–732CrossRefPubMedGoogle Scholar
  37. Schlingemann J, Hess J, Wrobel G et al. (2003) Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer 104:699–708CrossRefPubMedGoogle Scholar
  38. Schreiber M, Kolbus A, Piu F et al. (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13:607–619CrossRefPubMedGoogle Scholar
  39. Schubert S, Gül DC, Grunert HP et al. (2003) RNA cleaving ‘10-23’ DNAzymes with enhanced stability and activity. Nucleic Acid Res 31:5982–5992CrossRefPubMedGoogle Scholar
  40. Segrelles C, Ruiz S, Perez P et al. (2002) Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21:53–64CrossRefPubMedGoogle Scholar
  41. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131–E136CrossRefPubMedGoogle Scholar
  42. She QB, Chen N, Bode AM et al. (2002) Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 62:1343–1348PubMedGoogle Scholar
  43. Szabowski A, Maas-Szabowski N, Andrecht S et al. (2000) c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 103:745–755CrossRefPubMedGoogle Scholar
  44. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142CrossRefPubMedGoogle Scholar
  45. Van Beveren C, van Straaten F, Curran T et al. (1983) Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell 32:1241–1255CrossRefPubMedGoogle Scholar
  46. Wagner EF (2001) AP-1 reviews. Oncogene 20:2333–2497CrossRefGoogle Scholar
  47. Wang XJ, Greenhalgh DA, Donehower LA et al. (2000) Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol Carcinog 29:67–75CrossRefPubMedGoogle Scholar
  48. Wang XJ, Greenhalgh DA, Lu XR et al. (1995) TGF alpha and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas. Oncogene 10:279–289PubMedGoogle Scholar
  49. Weston CR, Davis RJ (2007) The JNK signal transduction pathway. Curr Opin Cell Biol 19:142–149CrossRefPubMedGoogle Scholar
  50. Weston CR, Wong A, Hall JP et al. (2004) The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci USA 101:14114–14119CrossRefPubMedGoogle Scholar
  51. Wicki A, Christofori G (2007) The potential role of podoplanin in tumour invasion. Br J Cancer 96:1–5CrossRefPubMedGoogle Scholar
  52. Yao D, Alexander CL, Quinn JA et al. (2008) Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci 121:1758–1769CrossRefPubMedGoogle Scholar
  53. Young MR, Farrell L, Lambert P et al. (2002) Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun. Mol Carcinog 34:72–77CrossRefPubMedGoogle Scholar
  54. Young MR, Li JJ, Rincon M et al. (1999) Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 96:9827–9832CrossRefPubMedGoogle Scholar
  55. Young MR, Yang HS, Colburn NH (2003) Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol Med 9:36–41CrossRefPubMedGoogle Scholar
  56. Zenz R, Eferl R, Kenner L et al. (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437:369–375CrossRefPubMedGoogle Scholar
  57. Zenz R, Scheuch H, Martin P et al. (2003) c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 4:879–889CrossRefPubMedGoogle Scholar
  58. Zhang G, Dass CR, Sumithran E et al. (2004) Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 96:683–696CrossRefPubMedGoogle Scholar
  59. Zhang G, Luo X, Sumithran E et al. (2006) Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 25:7260–7266CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.DKFZ-ZMBH Alliance, Division of Signal Transduction and Growth Control (A100)German Cancer Research Center (DKFZ)HeidelbergGermany

Personalised recommendations